Asana BioSciences, a clinical-stage biopharmaceutical company, was founded in 2014 with the mission to develop novel, clinically differentiated, best-in-class products that address unmet medical needs and provide new treatment options for cancer patients and those suffering from inflammatory conditions.
Asana’s inflammation and immunology assets address indications such as chronic hand eczema, atopic dermatitis, systemic lupus, and many other immunological and skin diseases. Asana’s oncology assets target advanced or metastatic cancers, including melanoma, non-small cell lung cancer, colorectal cancer, ovarian cancer and other solid tumors. Asana’s proprietary portfolio comprises of multiple drugs, both small molecules and a biologic (antibody-drug conjugate).
Utilizing a highly efficient, virtual drug discovery and development model, which is supported by globally recognized scientific advisors and key opinion leaders, Asana develops best-in-class novel therapeutics and seek collaboration/out-licensing partners upon completion of Phase 1 or Phase 2 trials for further development, marketing authorization and commercialization to maximize the potential of the product.
Seven successful INDs were filed in a short span after founding of Asana and multiple clinical proof of concepts studies have been completed in oncology and immunology/inflammation therapeutic categories. Gusacitinib, Asana’s lead immunology asset, is entering phase 3 development. Asana’s lead oncology asset (ASN007 or ERAS-007) has completed phase 1 trials in cancer patients.
Multiple drugs from Asana’s portfolio have already been out-licensed/partnered with other biotech companies for further development and commercialization.